These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12474482)

  • 1. Compassionate use of sitamaquine in an HIV-positive patient with visceral leishmaniasis.
    Rashid JR; Nyakundi PM; Kirigi G; Kinoti D; Wasunna MK
    Trans R Soc Trop Med Hyg; 2002; 96(5):533-4. PubMed ID: 12474482
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
    Wasunna MK; Rashid JR; Mbui J; Kirigi G; Kinoti D; Lodenyo H; Felton JM; Sabin AJ; Albert MJ; Horton J
    Am J Trop Med Hyg; 2005 Nov; 73(5):871-6. PubMed ID: 16282296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
    Jha TK; Sundar S; Thakur CP; Felton JM; Sabin AJ; Horton J
    Am J Trop Med Hyg; 2005 Dec; 73(6):1005-11. PubMed ID: 16354802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.
    Rybniker J; Goede V; Mertens J; Ortmann M; Kulas W; Kochanek M; Benzing T; Arribas JR; Fätkenheuer G
    Int J Infect Dis; 2010 Jun; 14(6):e522-5. PubMed ID: 19726213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.
    Collini P; Premchand N; Lockwood D; Greig J
    Ann Trop Med Parasitol; 2009 Jul; 103(5):455-9. PubMed ID: 19583915
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient.
    Alsina-Gibert M; López-Lerma I; Martinez-Chamorro E; Herrero-Mateu C
    Arch Dermatol; 2006 Jun; 142(6):787-9. PubMed ID: 16785393
    [No Abstract]   [Full Text] [Related]  

  • 8. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Santos J; Rivero A; Márquez M
    An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659
    [No Abstract]   [Full Text] [Related]  

  • 9. Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients.
    Angarano G; Maggi P; Coppola SL; Cavaliere RL
    Eur J Clin Microbiol Infect Dis; 1998 May; 17(5):365-7. PubMed ID: 9721971
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.
    Dietze R; Carvalho SF; Valli LC; Berman J; Brewer T; Milhous W; Sanchez J; Schuster B; Grogl M
    Am J Trop Med Hyg; 2001 Dec; 65(6):685-9. PubMed ID: 11791957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An HIV-positive man with tattoo induration.
    López-Medrano F; Costa JR; Rodriguez-Peralto JL; Aguado JM
    Clin Infect Dis; 2007 Jul; 45(2):220-1, 267-8. PubMed ID: 17578782
    [No Abstract]   [Full Text] [Related]  

  • 12. Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS).
    Pourahmad M; Hooshmand F; Rahiminejad M
    Int J Dermatol; 2009 Jan; 48(1):59-61. PubMed ID: 19126052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS and leishmaniasis.
    Davidson RN
    Genitourin Med; 1997 Aug; 73(4):237-9. PubMed ID: 9389941
    [No Abstract]   [Full Text] [Related]  

  • 14. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients.
    Petit N; Parola P; Dhiver C; Gastaut JA
    J Antimicrob Chemother; 1996 Jul; 38(1):154-7. PubMed ID: 8858471
    [No Abstract]   [Full Text] [Related]  

  • 16. Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance.
    Loiseau PM; Cojean S; Schrével J
    Parasite; 2011 May; 18(2):115-9. PubMed ID: 21678786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engima of therapeutic failure in visceral leishmaniasis.
    Arya SC
    J Assoc Physicians India; 1993 Mar; 41(3):155-8. PubMed ID: 8226600
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV-associated visceral leishmaniasis.
    Pintado V; López-Vélez R
    Clin Microbiol Infect; 2001 Jun; 7(6):291-300. PubMed ID: 11442562
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.
    Sundar S; Sinha PK; Dixon SA; Buckley R; Miller AK; Mohamed K; Al-Banna M
    Am J Trop Med Hyg; 2011 Jun; 84(6):892-900. PubMed ID: 21633025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavalent antimony and interferon-gamma.
    de Górgolas M; Castrillo JM; Fernández Guerrero ML
    Clin Infect Dis; 1993 Jul; 17(1):56-58. PubMed ID: 8353246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.